<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535820</url>
  </required_header>
  <id_info>
    <org_study_id>CR100412</org_study_id>
    <secondary_id>NRGEEPCON1017</secondary_id>
    <nct_id>NCT01535820</nct_id>
  </id_info>
  <brief_title>The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women</brief_title>
  <official_title>A Bioequivalence Study to Evaluate the Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence of the contraceptive hormones of&#xD;
      ORTHO EVRA when the patch is applied with and without an adhesive overlay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (the study drug is assigned by chance), open-label (all people know the&#xD;
      identity of the intervention), single-center, single-application, 2-way crossover study&#xD;
      (participants receive different interventions sequentially during the trial) of ORTHO EVRA&#xD;
      with and without an adhesive overlay. ORTHO EVRA is a combination transdermal (through the&#xD;
      skin) contraceptive patch containing 6.00 mg of the progestin norelgestromin (NGMN) and 0.75&#xD;
      mg of the estrogen, ethinyl estradiol (EE). The participants will be randomly assigned to 1&#xD;
      of 2 possible treatment sequences to ensure that they receive both of the following&#xD;
      treatments, 1 in each period: - Treatment A: ORTHO EVRA patch applied to the buttock with an&#xD;
      adhesive overlay applied over the transdermal contraceptive system; - Treatment B: ORTHO EVRA&#xD;
      patch applied to the buttock without an overlay. The study consists of a screening phase; an&#xD;
      open-label treatment phase consisting of 2 single-application 7-day treatment periods; and&#xD;
      end-of-study or withdrawal assessments done upon completion of the 240-hour pharmacokinetic&#xD;
      sampling on Day 11 of Period 2 or upon withdrawal. Pharmacokinetic evaluations explore how&#xD;
      the drug is absorbed in the body, distributed within the body, and how it is removed from the&#xD;
      body over time. The two treatment periods will be separated by a washout period (period when&#xD;
      receiving no treatment) of 21 days. During the study, safety and tolerability will also be&#xD;
      assessed. The total duration of participation in the study for an individual will be&#xD;
      approximately 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NGMN plasma concentrations (Periods 1 and 2)</measure>
    <time_frame>At 0, 24, 48, 72, 120, 168, 171, 174, 180, 192, 204, 216, and 240 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EE plasma concentrations (Periods 1 and 2)</measure>
    <time_frame>At 0, 24, 48, 72, 120, 168, 171, 174, 180, 192, 204, 216, and 240 hours.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of NGMN (Periods 1 and 2)</measure>
    <time_frame>At 0, 24, 48, 72, 120, 168, 171, 174, 180, 192, 204, 216, and 240 hours.</time_frame>
    <description>Pharmacokinetic parameters of NGMN as measured by AUC, Cmax, tmax, and Css.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of EE (Periods 1 and 2)</measure>
    <time_frame>At 0, 24, 48, 72, 120, 168, 171, 174, 180, 192, 204, 216, and 240 hours.</time_frame>
    <description>Pharmacokinetic parameters of EE as measured by AUC, Cmax, tmax, and Css.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events as a measure of safety and tolerability</measure>
    <time_frame>Approximately 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients with changes in clinical laboratory test values, physical examination results, and vital signs measurements</measure>
    <time_frame>Approximately 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay</intervention_name>
    <description>NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.</description>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_label>Treatment sequence BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay</intervention_name>
    <description>NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.</description>
    <arm_group_label>Treatment sequence AB</arm_group_label>
    <arm_group_label>Treatment sequence BA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30 kg/m2 (inclusive), and body weight not less&#xD;
             than 50 kg and not more than 90 kg&#xD;
&#xD;
          -  Must be surgically sterile with intact ovaries, abstinent, or, if sexually active, be&#xD;
             practicing an effective method of non-hormonal birth control (eg, non-hormonal&#xD;
             intrauterine device, double-barrier method, male partner sterilization) before entry&#xD;
             and throughout the study&#xD;
&#xD;
          -  Completed her last term pregnancy at least 90 days before admission to the study site&#xD;
&#xD;
          -  History of regular menstrual cycles (occurring every 25 to 35 days)&#xD;
&#xD;
          -  Must not be pregnant or lactating&#xD;
&#xD;
          -  Blood pressure between 90 and 140 mmHg systolic (inclusive), and no higher than 90&#xD;
             mmHg diastolic&#xD;
&#xD;
          -  Hemoglobin equal or more than 12.0 at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of smoking or use of nicotine-containing substances&#xD;
&#xD;
          -  Used steroid hormonal therapy within 30 days before admission to the study&#xD;
&#xD;
          -  Received a Depo Provera® injection in the 6 months before admission to the study&#xD;
&#xD;
          -  History or presence of disorders commonly accepted as contraindications to sex&#xD;
             hormonal therapy&#xD;
&#xD;
          -  History of or current clinically significant medical illness or any other condition&#xD;
             that the investigator considers should exclude the patient or that could interfere&#xD;
             with the interpretation of the study results&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>ORTHO EVRA</keyword>
  <keyword>Contraceptive hormones</keyword>
  <keyword>Transdermal patch</keyword>
  <keyword>Progestin norelgestromin (NGMN)</keyword>
  <keyword>Estrogen ethinyl estradiol (EE)</keyword>
  <keyword>JNJ-93964</keyword>
  <keyword>JNJ-622206</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ortho Evra</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

